Drug intelligence / Profile preview

RC-08

Development stage: Preclinical
Lead developer: Taizhou Hongyun Pharmaceutical
Modality: Small Molecules

Overview

RC-08 is a small molecule drug candidate that acts as an inhibitor of HPK1 (hematopoietic progenitor kinase 1), also known as mitogen-activated protein kinase kinase kinase kinase 1. It is being developed primarily for the treatment of neoplasms, with a focus on solid tumors. The drug was initially developed by Taizhou Hongyun Pharmaceutical and, as of April 2025, remains in preclinical development. By inhibiting HPK1, RC-08 aims to modulate immune signaling pathways relevant to cancer therapy[1].

Targets

MAP4K1 (Hematopoietic progenitor kinase 1)

Beyond the preview

Go deeper on RC-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RC-08.

Explore the full profile